Your browser doesn't support javascript.
Assessment and management of the SARS-CoV-2 infection: A secondary center experience: Approach to COVID-19 infection
Annals of Clinical and Analytical Medicine ; 13(3):309-313, 2022.
Article in English | EMBASE | ID: covidwho-2287692
ABSTRACT

Aim:

The aim of the study was to evaluate the management and outcomes of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a secondary hospital. Material(s) and Method(s) This study included 699 hospitalized patients who had positive rRT-PCR for SARS-CoV-2 and/or typical findings of COVID-19 on chest computed tomography (CT). Demographics, comorbidities, initial laboratory tests on admission, treatment modalities, complications and outcomes were evaluated retrospectively. Result(s) The mean age was 57.0+/-15.6 (range16-94 years), and male to female ratio was 1.24;58.7% of the patients had at least one underlying comorbidity, the most common was hypertension;18.1% of the patients had lymphopenia, 35.7% hyperferritinemia, 58.3% had increased lactate dehydrogenase, and 58.5% had increased D-dimer. Chest CT revealed moderate and severe stages in 57.9% of the patients. Hydroxychloroquine was given to 37.2% and favipiravir to 67.1% of the patients. No significant difference was observed between treatment groups in terms of mortality (P=0.487);5.8% of the patients were transferred to the ICU, 75.6% of whom needed non-invasive and 36.5% invasive mechanical ventilation. The overall case-fatality rate was 0.9. Discussion(s) Older age, male gender, low lymphocyte count, CT findings, including bilateral involvement and severe stage were significantly associated with poor prognosis and mortality.Copyright © 2022, Derman Medical Publishing. All rights reserved.
Keywords
Adults, covid-19, Outcome, SARS-CoV-2, Treatment, adult, aged, ageusia, anosmia, article, asthma, blood cell count, bradycardia/si [Side Effect], cardiovascular disease, case fatality rate, chronic obstructive lung disease, computer assisted tomography, coronavirus disease 2019/dt [Drug Therapy], coughing, creatinine clearance, diabetes mellitus, diarrhea, disease assessment, dyspnea, electrocardiography, female, fever/dt [Drug Therapy], ground glass opacity, headache, human, hyperferritinemia, hyponatremia, hypotension, hypoxemia, intensive care unit, lymphocyte count, lymphocytopenia/dt [Drug Therapy], macrophage activation syndrome/dt [Drug Therapy], major clinical study, male, myalgia, nasopharyngeal swab, neutrophilia/dt [Drug Therapy], observational study, oropharyngeal swab, oxygen saturation, pleura effusion, QT prolongation, rash/si [Side Effect], real time reverse transcription polymerase chain reaction, respiratory failure, retrospective study, Severe acute respiratory syndrome coronavirus 2, tachypnea, thrombocytopenia/dt [Drug Therapy], venous thromboembolism/dt [Drug Therapy], ascorbic acid/dt [Drug Therapy], ascorbic acid/pv [Special Situation for Pharmacovigilance], azithromycin/cb [Drug Combination], azithromycin/dt [Drug Therapy], azithromycin/po [Oral Drug Administration], azithromycin/pv [Special Situation for Pharmacovigilance], C reactive protein/ec [Endogenous Compound], D dimer/ec [Endogenous Compound], enoxaparin/dt [Drug Therapy], enoxaparin/pv [Special Situation for Pharmacovigilance], enoxaparin/sc [Subcutaneous Drug Administration], favipiravir/ae [Adverse Drug Reaction], favipiravir/dt [Drug Therapy], favipiravir/pv [Special Situation for Pharmacovigilance], fibrinogen/ec [Endogenous Compound], heparin/dt [Drug Therapy], heparin/pv [Special Situation for Pharmacovigilance], hydroxychloroquine/cb [Drug Combination], hydroxychloroquine/dt [Drug Therapy], hydroxychloroquine/po [Oral Drug Administration], hydroxychloroquine/pv [Special Situation for Pharmacovigilance], lactate dehydrogenase/ec [Endogenous Compound], lopinavir/dt [Drug Therapy], lopinavir/pv [Special Situation for Pharmacovigilance], low molecular weight heparin/dt [Drug Therapy], low molecular weight heparin/pv [Special Situation for Pharmacovigilance], methylprednisolone/dt [Drug Therapy], methylprednisolone/iv [Intravenous Drug Administration], methylprednisolone/pv [Special Situation for Pharmacovigilance], oseltamivir/cb [Drug Combination], oseltamivir/dt [Drug Therapy], oseltamivir/pv [Special Situation for Pharmacovigilance], procalcitonin/ec [Endogenous Compound], ritonavir/dt [Drug Therapy], ritonavir/pv [Special Situation for Pharmacovigilance], steroid/dt [Drug Therapy], steroid/pv [Special Situation for Pharmacovigilance], tocilizumab/dt [Drug Therapy], tocilizumab/pv [Special Situation for Pharmacovigilance], face mask, nasal cannula

Full text: Available Collection: Databases of international organizations Database: EMBASE Language: English Journal: Annals of Clinical and Analytical Medicine Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: EMBASE Language: English Journal: Annals of Clinical and Analytical Medicine Year: 2022 Document Type: Article